
    
      This trial is an investigator-initiated prospective, single-center, placebo-controlled,
      double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice
      daily) for 90-days following a type 2 myocardial infarction. The primary feasibility outcome
      is time to recruitment of 100 participants, stratified by sex.
    
  